Valeant in talks to buy Actavis for over $13 bln -WSJ
April 26 (Reuters) - Canada's biggest listed drug maker, Valeant Pharmaceuticals International Inc, is in talks to buy generic drugmaker Actavis Inc for more than $13 billion, Wall Street Journal reported, citing people familiar with the matter.
The companies had been working towards an all-stock deal, when some of Actavis' directors came out against it around the middle of this week. But executives on the two sides are still working to resurrect the deal, the journal said.
Valeant said in February it was in talks to make more acquisitions, and it remains open to discuss a potential "merger of equals."
Shares of Actavis, which has a market capitalization of $12.9 billion, have risen about 12 percent in the past three months.
Actavis, the third-largest global generic drugmaker, changed its name in January from Watson after buying Actavis as part of its strategy to expand in international markets and offer more specialty drugs.
Valeant and Actavis could not be immediately reached for comments outside of business hours.
© Thomson Reuters 2017 All rights reserved.